AKT1 and liposarcoma: Moreover, several low-molecular-weight multi-kinase inhibitors targeting MET, AXL, IGF1R, EGFR, VEGFR2 and PDGFR-β could be effective in the types of liposarcoma characterized by abnormalities in PI3K/Akt/mTOR signaling and the associated deregulation of other cascades [98,99,100,101,102].